Companies / Germany
Shire To Market Orphan Drug Following Jerini Acquisition
July 2008 | Company News AlertNot wanting to be left behind in the current spate of biotech acquisitions, UK based Shire has struck a deal to acquire German firm Jerini for EUR349mn (US$548mn). In what Jerini describes as a strategic partnership, the UK firm will pay EUR6.25 (US$9.81) per share - 73% more than Jerini's closing price on July 2
Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Western Europe Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Western Europe Pharma & Healthcare Insight please click on the trial link below.
